J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993 This issue


Multiple Myeloma: What Do We Do About Immunodeficiency?

Linrong Li1, Liang Wang2✉

1. Second Clinical Medical College, Southern Medical University, Guangzhou, China.
2. Department of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Li L, Wang L. Multiple Myeloma: What Do We Do About Immunodeficiency?. J Cancer 2019; 10(7):1675-1684. doi:10.7150/jca.29993. Available from https://www.jcancer.org/v10p1675.htm

File import instruction


Multiple myeloma (MM) is an incurable hematological malignancy. Immunodeficiency results in the incapability of immunity to eradicate both tumor cells and pathogens. Immunotherapies along with antibiotics and other anti-infectious agents are applied as substitutes for immunity in MM. Immunotherapies including monoclonal antibodies, immune checkpoints inhibitors, affinity- enhanced T cells, chimeric antigen receptor T cells and dendritic cell vaccines are revolutionizing MM treatment. By suppressing the pro-inflammatory milieu and pathogens, prophylactic and therapeutic antibiotics represent anti-tumor and anti-infection properties. It is expected that deeper understanding of infection, immunity and tumor physio-pathologies in MM will accelerate the optimization of combined therapies, thus improving prognosis in MM.

Keywords: immunodeficiency, multiple myeloma, immunotherapy, antibiotic